Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First disclosure of a mutant calreticulin (mCALR)